PTPN2 and inflammatory bowel disease: In particular, the novel finding of an association of the PTPN2 rs7234029 risk allele with nonresponse to anti-IL-12/23 treatment in CD patients calls for further investigation, as there is an urgent need for biomarkers to predict therapy responses in IBD patients.